Abcam acquires rights to over 700 Roche products in new licensing deal

pharmafile | January 22, 2018 | News story | Sales and Marketing Abcam, Roche, partnership, pharma 

Roche has entered a licensing agreement Abcam which gives the British biotech exclusive access to the marketing rights for 760 of the Swiss pharma giant’s products, all of which are for research use only (RUO).

The full range of products represents the complete portfolio of Spring Bioscience Corporation, a California-based biotech that Roche acquired in 2007, and includes 243 antibodies for use in rabbits, in addition to more than 500 other antibodies.

As part of the deal, Abcam will have the rights to any future antibodies developed by Spring which Roche decides to commercialise for an initial period of 10 years. Roche retains the right to use antibodies for internal research and as companion diagnostic tools.

Abcam will begin commercialising and selling the acquired antibodies from 21 February.

The deal marks the latest in a series of moves by Abcam to expand its portfolio, which now includes more than 120,000 products. Since 2011, the biotech has made a number of acquisitions to this end, including AxioMx, Ascent Scientific, Epitomics, Firefly Bioworks and MitoSciences.

Matt Fellows

Related Content

EC approves Roche’s Evrysdi for babies under two months with SMA

Roche has announced that the European Commission (EC) has approved the extension of Evrysdi’s marketing …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content